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Abstract
This study was performed to determine the effects of selenium supplementation on clinical symptoms and gene expression related
to inflammatory markers in infertile women with polycystic ovary syndrome (PCOS) who were candidate for in vitro fertilization
(IVF). Thirty-six women candidate for IVF were recruited in this randomized double-blinded, placebo-controlled trial. They (n =
18/group) were randomly assigned into intervention groups to take either 200 μg/day of selenium or placebo for 8 weeks. RT-
PCR findings indicated that selenium supplementation downregulated gene expression of interleukin-1 (IL-1) (P < 0.004) and
tumor necrosis factor alpha (TNF-α) (P = 0.02) in lymphocytes of patients with PCOS compared with the placebo. In addition,
selenium supplementation upregulated gene expression of vascular endothelial growth factor (VEGF) (P = 0.001) in lympho-
cytes of patients with PCOS compared with the placebo. Selenium supplementation had no significant effect on clinical symp-
toms and gene expression of IL-8 (P = 0.10) and transforming growth factor beta (TGF-β) (P = 0.63). Overall, our findings
documented that selenium supplementation for 8 weeks to infertile women candidate for IVF improved IL-1, TNF-α, and VEGF
gene expression, though selenium had no effect on clinical symptoms and, IL-8 and TGF-β gene expression. Clinical trial
registration number: http://www.irct.ir: IRCT20170513033941N23.
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Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous disor-
der in reproductive-aged women. The main cause of PCOS
remains unknown and is likely multifactorial. Insulin resis-
tance and a low-grade inflammation play critical roles in the
pathological process of this syndrome [1]. Women suffering
from PCOS are often subfertile secondary to ovulatory dys-
function, impaired oocyte quality, and low endometrial recep-
tivity [2]. In vitro fertilization (IVF) recommended as an
assisted reproduction technology for PCOS-related infertility
when patients do not respond to ovulation induction agents
[3]. PCOS women undergoing IVF treatment are known to
possess a higher risk of developing some complication includ-
ing increased cancelation rate and ovarian hyperstimulation
syndrome [4, 5]. Some evidence suggested that inflammatory
cytokine profiles influence oocyte fertilization and correlate
with pregnancy success in women who conceive using IVF
setting [6]. In addition, it is reported that the serum concentra-
tion of some growth factor such as vascular endothelial
growth factor (VEGF) is associated with embryo quality in
these women [7].
Earlier, in a meta-analysis study by Ju et al. [8], it has been
reported that supplementation with selenium improved in-
flammation and oxidative stress. Few studies investigated
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the effects of selenium supplementation among PCOS pa-
tients. Previously, we observed that taking selenium supple-
mentation in subjects with PCOS had beneficial effects on
glycemic and lipid profiles [9]. Moreover, an experiment by
Zhang et al. [10] showed that selenium deficiency exacerbated
uterine tissue destruction and increased the mRNA expression
of inflammatory cytokines in the mice model of endometritis.
Interestingly, selenium administration in this study led to a
decrease in tumor necrosis factor-α (TNF-α), interleukin-
(IL-) 1β and IL-6 gene expression.
Selenium has both anti-inflammatory and anti-oxidant
properties. It may alleviate the inflammatory gene expression
by inhibiting the activation of mitogen-activated protein
(MAP) kinase and nuclear factor-kappaB (NF-κB) pathways
[11]. Hence, this study aimed to evaluate the effects of seleni-
um supplementation on clinical symptoms and gene expres-
sion related to inflammatory biomarkers and VEGF in women
with PCOS candidate for IVF.
Methods
Trial Design and Participants’ Characteristics
This randomized, double-blinded, placebo-controlled trial
was registered by Iranian website for clinical trials registration
(http://www.irct.ir: IRCT20170513033941N23). Between
February and August 2018, 40 infertile women with PCOS,
at age 18 to 40 years, who were candidate for IVF without
prior IVF, were randomly enrolled in this investigation. To
confirm PCOS diagnosis, Rotterdam criteria was used [12].
Subjects with metabolic abnormalities such as diabetes,
impaired glucose tolerance, and thyroid dysfunction were
excluded from the trial. This study was approved by the
research ethics committee of Shahid Beheshti University of
Medical Sciences (SUMS), Tehran, Iran. All individuals
signed written informed consent.
Intervention
At first, patients were matched according to BMI (< 25 and ≥
25 kg/m2), age (< 30 and ≥ 30 y), dosage of medication used
and ovarian reserve (anti-Müllerian hormone) of PCOS. Then,
subjects were randomly allocated into intervention groups to
intake either 200 μg/day selenium as selenium yeast (Nature
Made, California, USA) (n = 18) or placebo (Barij Essence,
Kashan, Iran) (n = 18) for 8 weeks. Due to a lack of evidence
about the appropriate dosage of selenium for infertile patients
with PCOS candidate for IVF, we used the abovementioned
dose of selenium based on a previous study in patients with
PCOS [9]. Placebos and selenium supplements were exactly
matched in terms of appearance, smell, shape, and packaging.
To randomize enrolled patients, computer-generated random
numbers were used. Allocation and randomization were
concealed from both the participants and researchers until fi-
nal analyses completion. Adherence to the placebos and sup-
plements, during the trial, was checked by asking participants
to bring the medication containers back. Patients completed
dietary records at weeks 0, 4, and 8 of the trial.
Assessment of Outcomes
TNF-α gene expression was measured as the primary out-
come and other gene expression associated with inflammation
were considered as the secondary outcomes. Fasting blood
samples (15 mL) were collected at the initiation and end of
the 8-week investigation at Mahdieh Hospital (Tehran, Iran).
Isolation of Lymphocyte Cells
Lymphocyte cells were extracted from blood samples, using
50% percoll (Sigma-Aldrich, Dorset, UK). Viability test and
cell count were done using trypan blue, DNA, and RNA ex-
traction [13].
RNA Extraction and Real-Time PCR
RNA was extracted from blood samples using RNX-plus kit
(Cinnacolon, Tehran, Iran). RNA suspension was frozen at −
20 °C until cDNA was derived. Following the extraction of
total RNAs from each sample, RNA was quantified using a
UV spectrophotometer. Using Moloney murine leukemia vi-
rus reverse transcriptase (RT), isolated RNAwas reverse tran-
scribed to cDNA library. IL-1, IL-8, transforming growth fac-
tor beta (TGF-β), TNF-α, and VEGF were carried out on
lymphocytes, using SYBR green detection and Amplicon
Kit and applying quantitative RT-PCR and Light Cycler tech-
nology (Roche Diagnostics, Rotkreuz, Switzerland) (Table 1).
The primers of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were used as a housekeeping gene.
Statistical Methods
Kolmogorov-Smirnov test was used to assess the normality of
data. To determine the differences in gene expression of in-
flammation and anthropometric measures between interven-
tion groups, independent samples t test was applied.
Differences in proportions were evaluated by Fisher’s exact
test. To control confounding variables, including dosage of
medication used, we used analysis of covariance
(ANCOVA). The P values of < 0.05 were considered statisti-
cally significant. Statistical analyses were done using the
Statistical Package for Social Science version 18 (SPSS Inc.,
Chicago, Illinois, USA).
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Results
Two dropouts were reported in each intervention group, due to
personal reasons. Overall, 36 participants [infertile women
with PCOS candidate for IVF receiving selenium (n = 18)
and placebo (n = 18)] completed the study (Fig. 1).
Compliance rate in this study was more than 90%. No side
effects were reported following the supplementation of sele-
nium in women with PCOS in this study.
Anthropometric measures were not statistically different
between intervention groups (Table 2). Moreover, following
selenium supplementation, IVF outcomes including endome-
trial thickness, number of oocytes retrieved, number of fertil-
ized oocytes, fertilization rate, pregnancy rate, and number of
embryo were not significantly different between supplement-
ed and placebo groups.
The average of dietary intakes of energy, carbohydrates,
fats, proteins, saturated fatty acids, monounsaturated fatty
acids, polyunsaturated fatty acids, cholesterol, total dietary
fiber, selenium, zinc, magnesium and manganese was also
not significantly different between the two groups throughout
the treatment (Table 3).
RT-PCR findings indicated that selenium supplementation
downregulated gene expression of IL-1 (P < 0.004) and
TNF-α (P = 0.02) in lymphocytes of patients with PCOS
compared with the placebo (Fig. 2). Selenium supplementa-
tion had no significant effect on gene expression of IL-8 (P =
0.10) in lymphocytes of patients with PCOS.
Selenium supplementation upregulated gene expression of
VEGF (P = 0.001) in lymphocytes of patients with PCOS
compared with the placebo (Fig. 3). There was no significant
effect of selenium supplementation on the gene expression of
TGF-β (P = 0.63) in lymphocytes of patients with PCOS. In
addition, when we adjusted the analysis for dosage of medi-
cation used, findings did not change (for IL-1, P < 0.001; for
TNF-α, P = 0.03; for IL-8, P = 0.07; for VEGF, P = 0.001;
and for TGF-β, P = 0.69).
Discussion
In the present study, we investigated the effects of selenium
supplementation clinical symptoms and gene expression relat-
ed to inflammatory markers for 8 weeks in infertile women
with PCOS who were candidate for IVF treatment. We found
that supplementation with selenium improved gene expres-
sion of IL-1, TNF-α, and VEGF, but did not affect the gene
expression of other cytokines including IL-8 and TGF-β.
Previously, it is stated that the concentrations of inflamma-
tory markers such as TNF-α and IL-6 are elevated in follicular
fluid from PCOS patients undergoing IVF [14]. TNF-α is an
inflammatory cytokine which mediates insulin resistance and
is capable of promoting hyperandrogenism in PCOS patients
[1]. This cytokine involves in both physiological and patho-
logical conditions in reproductive tissues. Exaggerated
TNF-α activity may promote epithelial apoptosis, favors pel-
vic implantation, and impairs trophoblast cell fusion [15]. In
IVF treatment, TNF-α levels correlates with the poor quality
of oocyte and the reduced rates of fertilization [16]. In addi-
tion, IL-1 which is a key player in the local and systemic
inflammation has been known to stimulate the generation of
reactive oxygen species and activation of NF-κB pathways
[17]. The current research showed that selenium supplemen-
tation for 6 weeks downregulated the gene expression of
TNF-α and IL-1, but did not affect IL-8 and TGF-β mRNA
expression in PCOS patients whowere candidate for IVF. Few
studies have reported that deficiency of trace elements may
have effect on reproductive health [18, 19]. Among trace ele-
ments, selenium and zinc play an important role in sexual
development, menstrual cycle, and ovulation [20]. In addition,
there is a correlation between these nutrients and their deriv-
atives and spontaneous abortions and congenital
malformations [20]. In another study, it was seen a lack of
selenium in IVF patients [21]. Few studies have reported the
effects of selenium supplementation on metabolic profiles in
patients with PCOS. In a study conducted by Razavi et al.
Table 1 Specific primers used for
real-time quantitative PCR Gene Primer Product
size (bp)
Annealing
temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
IL-1 F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TNF-α F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
TGF-β F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
VEGF F: CTTCTGAGTTGCCCAGGAGA 216 54
R: CTCACACACACACAACCAGG
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL-1, interleukin-1; IL-8, interleukin-8; TNF-α, tumor
necrosis factor alpha; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor
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[22], selenium supplementation at a dosage of 200 μg/day for
8 weeks to patients with PCOS significantly improved few
reproductive outcomes, and biomarkers of inflammation and
oxidative stress. In addition, we have previously shown that
selenium and probiotic co-supplementation for 12 weeks to
women with PCOS had beneficial effects on mental health
parameters, total testosterone, hirsutism, and few biomarkers
of inflammation and oxidative stress [23]. Also, selenium sig-
nificantly decreased oxidative stress through transient receptor
potential cation channel subfamily V member 1 channels in
the neutrophils of patients with PCOS [24]. However, taking
200 μg/day selenium supplements for 12 weeks by women
Randomized (n=40)
Allocated to placebo (n=20)
Lost to follow-up due to
personal reasons (n=2)
Analyzed with ITT (n=18)
Allocated to intervention (n=20) 
Lost to follow-up due to personal
reasons (n=2)
Analyzed with ITT (n=18)
Assessed for eligibility (n=47)
Excluded (n=7) 
- Not meeting inclusion criteria (n=7)
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Fig. 1 Summary of patient flow
diagram
Table 2 General characteristics
of study participants Placebo group
(n = 18)
Selenium group
(n = 18)
P1
Age (y) 32.6 ± 3.5 32.1 ± 4.7 0.28
Height (cm) 163.9 ± 2.6 165.6 ± 3.1 0.07
Weight at study baseline (kg) 76.8 ± 6.5 74.5 ± 8.0 0.35
Weight at end-of-trial (kg) 77.0 ± 6.5 74.5 ± 8.1 0.32
Weight change (kg) 0.2 ± 0.8 0.1 ± 1.3 0.69
BMI at study baseline (kg/m2) 28.6 ± 2.5 27.2 ± 3.1 0.14
BMI at end-of-trial (kg/m2) 28.7 ± 2.5 27.2 ± 3.2 0.13
BMI change (kg/m2) 0.1 ± 0.3 0.03 ± 0.5 0.69
Gonal-F therapy (IU/day) 240.5 ± 70.7 256.1 ± 45.3 0.43
Outcomes of IVF at end-of-trial
Endometrial thickness (mm) 9.0 ± 1.6 9.6 ± 2.0 0.30
No. of oocytes retrieved (n) 17.7 ± 4.3 16.0 ± 5.4 0.31
Fertilization rate, % (n) 61.1 (11/18) 66.7 (12/18) 0.73†
Pregnancy rate, % (n) 27.8 (5/18) 33.3 (6/18) 0.71†
No. of embryo (n) 10.7 ± 2.3 11.9 ± 2.3 0.12
Data are means ± SDs; BMI, body mass index
1Obtained from independent t test
†Obtained from Fisher’s exact test
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with PCOS resulted in a marginally significant increase in
insulin concentrations [25]. Previously, our supporting study
indicated that a 6-week selenium supplementation in women
with gestational diabetes mellitus (GDM) reduced the gene
expression of TNF-α [26]. In addition, selenium administra-
tion led to a decrease in TNF-α and IL-1 gene expression
chicken with lead-induced spleen damage [27]. Moreover,
selenium supplementation downregulated inflammatory me-
diators TNF-α, IL-1B, and IL-6 gene expression in
Staphylococcus aureus-stimulated bovine mammary endothe-
lial cells [28]. However, 2 weeks’ supplementation with sele-
nium did not change plasma concentrations of inflammatory
markers including TNF-α levels in patients undergoing hema-
topoietic stem cell transplantation [29]. Given the negative
influences of the pro-inflammatory environment presenting
in polycystic ovaries, the alleviating of inflammation im-
proves endometrium function and enhance insulin action
[30]. Selenium supplementation may decrease gene expres-
sion of inflammatory cytokines through the suppressing of
phosphorylation in NF-κB and MAPK pathways [31]. In ad-
dition, modifying the cellular redox tone by selenoproteins
mediate the signaling of NF-κB and MAPK which in turn
resulted in reduced protein synthesis of inflammatory media-
tors [32]. Moreover, an in vitro study indicated that
selenoproteins inhibit histone acetylation of TNF-α gene pro-
moters in macrophage cell which may explain the regulation
of inflammatory gene expression by selenium [33].
In the present study, we demonstrated that selenium sup-
plementation for 6 weeks, upregulated VEGF mRNA expres-
sion in PCOS women candidate for IVF. Similarly, VEGF
expression was increased by selenium supplementation in
GDM women [26]. In addition, the administration of herbal
extract enriched with selenium increased the expression of
VEGF in rat model of Alzheimer’s disease [34]. Moreover,
topical application of selenium upregulated VEGF mRNA
expression in diabetic rats [35]. Although, selenium adminis-
tration did not change VEGF gene expression in an animal
model of epilepsy [36]. VEGF is a regulator of angiogenesis
which increases vascular permeability and induces capillary
formation. It is also implicated in reproductive performance
[37]. The abnormal gene expression of VEGF has been sug-
gested to be associated with low implantation rates and the
lack of clinical pregnancy after IVF attempt [38]. Decreased
gene expression of VEGF also increases susceptibility to pre-
Table 3 Mean dietary intakes of
study participants throughout the
study
Placebo group
(n = 18)
Selenium group
(n = 18)
P1
Energy (kcal/d) 2296 ± 298 2198 ± 310 0.33
Carbohydrates (g/d) 319.4 ± 69.9 303.6 ± 55.8 0.45
Protein (g/d) 82.1 ± 14.7 83.2 ± 18.2 0.85
Fat (g/d) 80.4 ± 11.1 76.3 ± 13.5 0.33
SFAs (g/d) 25.0 ± 4.2 24.4 ± 5.1 0.71
PUFAs (g/d) 24.3 ± 3.2 22.8 ± 5.7 0.30
MUFAs (g/d) 20.9 ± 4.9 21.1 ± 5.4 0.89
Cholesterol (mg/d) 229.1 ± 121.2 189.3 ± 73.4 0.24
TDF (g/d) 19.2 ± 5.0 19.8 ± 3.7 0.67
Selenium (μg/d) 55.2 ± 11.0 54.3 ± 8.0 0.79
Zinc (mg/d) 10.3 ± 2.4 9.8 ± 2.8 0.50
Magnesium (mg/d) 259.2 ± 52.2 254.3 ± 48.0 0.77
Manganese (mg/d) 2.1 ± 0.9 1.9 ± 0.7 0.32
Data are means± SDs; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated
fatty acids; TDF, total dietary fiber
1 Obtained from independent t test
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Fig. 2 Effect of the 8-week supplementation with selenium or placebo on expression ratio of IL-1, IL-8, and TNF-α gene in lymphocytes of polycystic
ovary syndrome women candidate for in vitro fertilization
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eclampsia during pregnancy [39]. The higher levels of VEGF
mRNA expression are associated with better endometrial
blood flow which in turn lead to successful implantation and
embryo transfer following IVF [40, 41]. Selenium may exert
regulatory effects on VEGF gene expression through
thioredoxin reductase action and balancing oxidation state
[42].
Overall, our findings documented that infertile women
with PCOS, who were candidate for IVF benefited from sele-
nium supplementation for 8 weeks in terms of improving the
gene expression of IL-1, TNF-α, and VEGF, though selenium
had no effect on clinical symptoms and gene expression of IL-
8 and TGF-β.
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